Vivo Capital IX, LLC - 04 Nov 2021 Form 3 Insider Report for IO Biotech, Inc. (IOBT)

Role
10%+ Owner
Signature
/s/ Jack Nielsen, as a Managing Member of Vivo Capital IX, LLC
Issuer symbol
IOBT
Transactions as of
04 Nov 2021
Net transactions value
$0
Form type
3
Filing time
04 Nov 2021, 21:33:18 UTC
Previous filing
25 Jun 2021
Next filing
12 Nov 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOBT Series C Preferred Stock 04 Nov 2021 Common Stock 2,365,545 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.
F2 The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.